HHV-6 IgM Test

Almost everyone on the planet carries human herpesvirus 6 (HHV-6). Most of us caught it before our second birthday, experienced a brief fever or rash, and then the virus settled into lifelong hibernation in our cells. For the vast majority of people, it stays quiet forever. But sometimes it reactivates, and when it does, your body sends up a specific flare: an antibody called IgM. Detecting that flare is what this test is designed to do.

A positive HHV-6 IgM result tells you that your immune system is actively responding to the virus right now, either because of a brand-new infection (rare in adults) or because the virus has reactivated from its dormant state. A negative result is the norm for most adults and simply means the virus is not currently active. This is a qualitative test: it answers "is the virus stirring?" rather than "how much virus is present?"

What HHV-6 IgM Actually Tells You

IgM (immunoglobulin M) is the first type of antibody your body makes when it encounters a threat. It appears within days of an infection or reactivation and typically fades within about two months in a new infection. In a reactivation, IgM can linger for two to three months and may remain detectable up to five or six months later. Because IgM is an early responder, a positive result points toward recent or ongoing viral activity, not a decades-old childhood exposure.

This is an important distinction from HHV-6 IgG, the other antibody type commonly tested. IgG sticks around for years, even for life, so a positive IgG result in an adult tells you almost nothing, since more than 90% of adults carry it. IgM, by contrast, is time-stamped. It signals something happening now.

When Reactivation Matters

For healthy adults, HHV-6 reactivation is usually harmless and may cause no symptoms at all. The virus wakes up briefly, the immune system pushes it back down, and you never know it happened. The story changes for people whose immune systems are suppressed, particularly those recovering from a bone marrow or stem cell transplant. In that setting, HHV-6 reactivation can cause serious complications.

A multicenter study of critically ill patients found that among those with detectable HHV-6 in their blood, about 10% developed clinically significant disease. Those who did had roughly 5 times higher odds of dying in the ICU compared to those whose virus stayed clinically silent. Encephalitis, a dangerous inflammation of the brain, is the most feared complication, typically appearing 15 to 45 days after a stem cell transplant, with survival rates around 62% at 240 days.

Chronic Fatigue and Other Associations

HHV-6 IgM has also drawn attention in the context of chronic fatigue syndrome. One study found that 60% of people with chronic fatigue syndrome had detectable IgM antibodies against an early HHV-6 protein, compared to lower rates in healthy controls. This is an association, not proof that HHV-6 causes the condition. Researchers have also reported links between HHV-6 activity and certain autoimmune conditions and lymphoproliferative disorders (cancers involving uncontrolled immune cell growth), but these findings are preliminary and have not been confirmed in large prospective studies.

Diagnostic Limitations You Should Know

This test has real accuracy constraints. In a study of children with confirmed recent primary infection, HHV-6 IgM had a sensitivity (the ability to correctly identify true positives) of 76.1% and a specificity (the ability to correctly rule out false positives) of 87.5%. That translates to an overall accuracy of 82.4%, meaning roughly 1 in 5 results may be wrong.

Professional guidelines from the Infectious Diseases Society of America explicitly state that serology (antibody-based blood testing) is not the preferred method for diagnosing HHV-6 infection. Quantitative PCR testing, which directly measures viral DNA in blood or spinal fluid, is considered more reliable. PCR can distinguish active viral replication from dormancy and can track whether treatment is working, something IgM cannot do.

When Results Can Be Misleading

The biggest confounder for this test is cross-reactivity with cytomegalovirus (CMV), a closely related virus. If you have a new CMV infection, your body may produce antibodies that react with HHV-6 test proteins, giving you a false-positive HHV-6 IgM result. Studies have shown that primary CMV infection can cause two- to four-fold increases in HHV-6 antibody levels. Any positive HHV-6 IgM should be interpreted alongside CMV testing to rule out this artifact.

In people with suppressed immune systems, particularly those with leukemia or transplant recipients, up to 40% of positive IgM results may occur without evidence of genuine acute infection. Immunosuppressive medications can also produce the opposite problem: suppressing antibody production enough to cause false-negative results. Commercial assays also do not distinguish between HHV-6A and HHV-6B, two distinct viral species with somewhat different disease associations.

A separate confounder applies to PCR testing rather than this serology test, but is worth knowing: about 1% of the population has HHV-6 DNA permanently embedded in their own chromosomes (called chromosomally integrated HHV-6). This causes persistently high viral DNA readings on PCR tests, mimicking active infection when the virus is not actually replicating. Serology is not affected by chromosomal integration, but if you are getting both tests done, this is an important caveat for your PCR results.

Reference Ranges

HHV-6 IgM does not have universally standardized clinical cutpoints. Results are reported as positive, negative, or equivocal, with thresholds set by each assay manufacturer. Because different labs use different testing platforms, a positive result at one lab may not mean the same thing as a positive result at another.

These categories are assay-dependent. In research settings, one specialized antibody-capture test used a signal-strength ratio cutoff of 0.5 for positivity, with ratios above 1.05 associated with reactivation. A different test that uses fluorescent-tagged antibodies used an IgM titer (a measure of antibody concentration) above 20 as the diagnostic threshold. These numbers apply only to those specific assays. Always compare your results within the same lab over time for the most meaningful interpretation.

Age Patterns in IgM Positivity

Because most people encounter HHV-6 in infancy, IgM positivity follows a predictable age curve. It first appears at 4 to 7 months of age (about 5% prevalence), peaks at 8 to 11 months (about 40%), stays detectable through ages 4 to 6 (about 17%), and drops to only 4 to 5% in adolescents and adults. One study found that all IgM-positive specimens came from children under 4.5 years old, with 98% specificity in adults over 35. In an adult, a positive result is much more likely to reflect viral reactivation than a first-ever infection.

Tracking Your Trend

A single HHV-6 IgM result is a snapshot, and a somewhat blurry one given the test's accuracy limitations. If your result is positive, the most informative next step is a follow-up test in 2 to 4 weeks. Paired blood samples showing a four-fold rise in HHV-6 IgG levels, or IgG seroconversion (going from negative to positive), provide much stronger evidence of recent infection than a single IgM reading.

For anyone investigating chronic symptoms like persistent fatigue, serial testing offers more useful information than any isolated result. If IgM is positive on one draw and negative 8 to 12 weeks later, that pattern is consistent with a self-limited reactivation. If IgM persists beyond 5 to 6 months, it may warrant further evaluation with PCR-based testing to quantify viral activity directly.

Because no published coefficient of variation exists for HHV-6 IgM, the test's reproducibility between draws is not well characterized. Compare your results within the same lab using the same assay to get the most consistent readings.